What more can we learn from DTC advertising? FDA's OPDP proposes new research
How do specifics around endorsements, mechanism of action and medication tracking in pharmaceutical ads impact consumers? That’s what the FDA’s Office of Prescription Drug Promotion (OPDP) wants to find out in three new studies.
OPDP has proposed three research projects on direct-to-consumer marketing, according to federal register notices posted last week. The studies would join the agency’s roster of 13 ongoing projects covering a wide range of topics, from accelerated approval disclosure to interpretation of drug names.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.